EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle‐Invasive Bladder Cancer Treated With Radical Cystectomy

Shingo Hatakeyama iD, Rikiya Taoka, Jun Miki, Ryoichi Saito, Wataru Fukuokaya, Yoshiyuki Matsui, Takashi Kawahara, Ayumu Matsuda, Taketo Kawai, Minoru Kato, Tomokazu Sazuka, Takeshi Sano iD und 29 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70782 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Shingo Hatakeyama und 40 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hirosaki University Graduate School of Medicine, Aomori, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cystectomy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the effects of the number of neoadjuvant chemotherapy (NAC) cycles and the addition of adjuvant chemotherapy (AC) after NAC on overall survival (OS) of patients with muscle‐invasive bladder cancer (MIBC). Patients and Methods We retrospectively evaluated 1687 patients with cT2‐4NxM0 MIBC who received radical cystectomy (RC) alone or RC plus perioperative chemotherapy at 36 institutions within the Japanese Urological Oncology Group. We evaluated the effect of the number of NAC cycles (2 vs. ≥ 3 cycles) and the addition of AC on OS.

Results

Among the 1687 patients analyzed, 946 received a median of three NAC cycles. The pathologic complete response rate did not significantly differ between those who received 2 (22.9%) and ≥ 3 cycles (27.5%, p = 0.112). Moreover, no significant difference in OS was observed between the groups ( p = 0.559). Multivariable Cox regression analysis showed that pathologic high‐risk (ypT2–4, pT3–4, or pN+) or cisplatin ineligibility were significantly associated with poor OS but not the number of NAC cycles ( p = 0.238). We identified 942 pathologically high‐risk patients after RC who were eligible for AC. Notably, no significant OS improvement was observed with the addition of AC as intensive perioperative chemotherapy after NAC. The primary limitation was selection bias from confounding by clinical indication.

Conclusions

Our findings showed that three or more NAC cycles and the addition of AC may have limited effects on OS in MIBC patients who received RC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCystectomyAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleChemotherapy, AdjuvantNeoadjuvant TherapyAgedPrognosisMiddle AgedRetrospective StudiesNeoplasm InvasivenessTreatment OutcomeNeoplasm StagingAdultAged, 80 and over

Stichwörter der Autor:innen

adjuvant chemotherapybladder cancerneoadjuvant chemotherapyoverall survivalradical cystectomy

Autor:innen und Institutionen

  • Department of Urology, Hirosaki University Graduate School of Medicine, Aomori, Japan.
  • Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology and Andrology, Kansai Medical University, Osaka, Japan.
  • Department of Urology, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Shingo Hatakeyama, Takeshi Sano, Fumihiko Urabe, Hiroaki Matsumoto

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Hatakeyama, S., Taoka, R., Miki, J., Saito, R., Fukuokaya, W., Matsui, Y., Kawahara, T., Matsuda, A., Kawai, T., Kato, M., Sazuka, T., Sano, T., Urabe, F., Kashima, S., Naito, H., Murakami, Y., Miyake, M., Daizumoto, K., Matsushita, Y., …, & Japanese Urological Oncology Group (2025). Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle‐Invasive Bladder Cancer Treated With Radical Cystectomy. Cancer Medicine. https://doi.org/10.1002/cam4.70782

Vancouver

Hatakeyama S, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, et al. Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle‐Invasive Bladder Cancer Treated With Radical Cystectomy. Cancer Medicine. 2025. doi:10.1002/cam4.70782

BibTeX
@article{Hatakeyama2025,
  author = {Hatakeyama, Shingo and Taoka, Rikiya and Miki, Jun and Saito, Ryoichi and Fukuokaya, Wataru and Matsui, Yoshiyuki and Kawahara, Takashi and Matsuda, Ayumu and Kawai, Taketo and Kato, Minoru and Sazuka, Tomokazu and Sano, Takeshi and Urabe, Fumihiko and Kashima, Soki and Naito, Hirohito and Murakami, Yoji and Miyake, Makito and Daizumoto, Kei and Matsushita, Yuto and Hayashi, Takuji and Inokuchi, Junichi and Sugino, Yusuke and Shiga, Ken-Ichiro and Yamaguchi, Noriya and Taguchi, Motohiro and Yasue, Keiji and Abe, Takashige and Nakanishi, Shotaro and Hashine, Katsuyoshi and Fujii, Masato and Nishihara, Kiyoaki and Matsumoto, Hiroaki and Tatarano, Shuichi and Wada, Koichiro and Sekito, Sho and Maruyama, Ryo and Nishiyama, Naotaka and Nishiyama, Hiroyuki and Kitamura, Hiroshi and Ohyama, Chikara and Japanese Urological Oncology Group, Japanese Urological Oncology Group},
  title = {Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle‐Invasive Bladder Cancer Treated With Radical Cystectomy},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70782}
}
Kostenlos starten →